Alpha 2.0
Login Register
» Authors » Andrew Artz

Andrew Artz

Explore the profile of Andrew Artz including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 100
Citations 2015
Followers 0
Related Specialties
Hematology
Oncology
Geriatrics
Top 10 Co-Authors
Ryotaro Nakamura
Ibrahim Aldoss
Guido Marcucci
Amandeep Salhotra
Haris Ali
Vinod Pullarkat
Monzr M Al Malki
Shukaib Arslan
Paul Koller
Anthony Stein
Published In
Biol Blood Marrow Transplant
Leuk Lymphoma
Transplant Cell Ther
Bone Marrow Transplant
Blood
Affiliations
Soon will be listed here.
Recent Articles
1.
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
Samuels D, Yao J, Samara Y, Yang D, Mokhtari S, Tiemann K, et al.
Front Immunol . 2025 Mar; 16:1543099. PMID: 40051639
Introduction: Hemorrhagic cystitis (HC) is an early complication after hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy). Hyperhydration can reduce HC, but may lead to fluid overload (FO), which has...
2.
Melphalan-based conditioning with post-transplant cyclophosphamide for peripheral blood stem cell transplantation: donor effect
Koller P, Othman T, Yang D, Mokhtari S, Samara Y, Blackmon A, et al.
Bone Marrow Transplant . 2025 Feb; PMID: 40016513
Fludarabine and melphalan (FM) conditioning offers effective disease control with an acceptable toxicity profile. Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis has improved transplant outcomes. We retrospectively reviewed patients...
3.
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)
Pourhassan H, Nguyen T, Yang D, Otoukesh S, Arslan S, Blackmon A, et al.
Cancers (Basel) . 2024 Dec; 16(23). PMID: 39682101
Background: The standard first-line treatment for acute graft-versus-host disease (aGvHD) is systemic, high-dose glucocorticoids which have historically had limited responses. Combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab...
4.
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study
Fei F, Jariwala A, Pullarkat S, Loo E, Liu Y, Tizro P, et al.
Int J Mol Sci . 2024 Sep; 25(18). PMID: 39337700
The accurate diagnosis and classification of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are challenging due to the overlapping pathological and molecular features of myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). We investigated the...
5.
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation
Desai A, Samara Y, Yang D, Ball B, Braun A, Koller P, et al.
Leuk Res . 2024 Aug; 145:107565. PMID: 39208597
Introduction: Allogeneic Hematopoietic cell transplantation (allo-HCT) remains the only curative therapy for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The impact of spliceosome mutations on allo-HCT outcome is unclear...
6.
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings
Otoukesh S, Yang D, Mokhtari S, Pourhassan H, Agrawal V, Arslan S, et al.
Bone Marrow Transplant . 2024 Aug; 59(11):1542-1551. PMID: 39147891
The optimal myeloablative conditioning regimen for ALL patients undergoing hematopoietic cell transplant (HCT) with an alternative donor is unknown. We analyzed HCT outcomes ALL patients (n = 269) who underwent...
7.
Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation
Arslan S, Desai A, Yang D, Mokhtari S, Tiemann K, Otoukesh S, et al.
Transplant Cell Ther . 2024 Aug; 30(10):1013.e1-1013.e12. PMID: 39122188
Allogeneic hematopoietic cell transplantation (HCT) remains the sole curative treatment for most patients with hematologic malignancies. A well-matched donor (related or unrelated) remains the preferred donor for patients undergoing allogeneic...
8.
In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy
Dandoy C, Adams J, Artz A, Bredeson C, Dahi P, Dodd T, et al.
Transplant Cell Ther . 2024 Jul; 30(10):942-954. PMID: 39067790
Immune effector cell (IEC) therapy represents a transformative advancement in oncology, leveraging the immune system to combat various malignancies. This article outlines a comprehensive framework for establishing and maintaining quality...
9.
Haplo-cord transplant. Realizing the potential of umbilical cord blood grafts. - A review of techniques and analysis of outcomes
Van Besien K, Liu H, Margevicius S, Fu P, Artz A, Chaekal O, et al.
Leuk Lymphoma . 2024 Jul; 65(10):1384-1397. PMID: 38949786
The combination of cord blood transplant with progenitor cells from partially HLA-matched adult donors has been used over the past two decades. In Europe and the US the adult donor...
10.
Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy
Aldoss I, Shan H, Yang D, Clark M, Al Malki M, Aribi A, et al.
Transplant Cell Ther . 2024 Jun; 30(8):788.e1-788.e9. PMID: 38876428
CD19-targeted chimeric antigen receptor T cell (CAR-T) therapy has led to unprecedented rates of complete remission (CR) in children and adults with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL), yet...